The American Heart Association and Bayer announced Thursday they will work together to advance research in three critical areas: cerebral small vessel disease, chronic kidney disease and heart failure.

The AHA Institute for Precision Cardiovascular Medicine is now accepting applications for three AHA-Bayer Innovation and Discovery Grants, funded by Bayer, which will provide $150,000 to each investigator.

The goal is to use precision medicine to advance scientific understanding and address unmet medical needs in cardiovascular and kidney diseases.

“Research in each of these areas is critical to provide individuals with better prevention and treatment options,” said Jennifer Hall, Ph.D., chief of the AHA Institute for Precision Cardiovascular Medicine. “Through this collaboration with Bayer, the American Heart Association is able to support vital research to develop a deeper understanding of these diseases.”

The institute uses enormous amounts of patient data — everything from a person’s genes to their environment and lifestyle — to find personalized approaches to prevent and treat heart disease and stroke.

Researchers worldwide can apply by April 13, 2017. Three awardees will be notified in June, with the 18-month awards beginning in July.